Patients who suffer from wet age-related macular degeneration (AMD), a leading cause of permanent vision loss, typically have to receive several anti-vascular endothelial growth (anti-VEGF) injections a year to maintain vision. This method of treating wet AMD is not only inconvenient for patients but places a considerable cost burden on the healthcare system. One company that has been working to offer a less invasive, less expensive alternative for wet AMD treatment, says it is currently preparing for commercial expansion in Europe.